MOTS-c: the mitochondrial peptide for metabolic health

The discovery of MOTS-c in 2015 by Dr. Changhan Lee, Dr. Pinchas Cohen, and their colleagues at the University of Southern California’s Leonard Davis School of Gerontology upended a quiet assumption that had governed mitochondrial biology for decades. The mitochondrial genome, a circular 16.5-kilobase loop inherited maternally and previously thought to encode only 13 proteins (all components of the electron transport chain), turned out to contain short open reading frames within its ribosomal RNA genes that produce signaling peptides with systemic metabolic effects.¹ MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) was the second such peptide characterized by the Cohen lab, following humanin, and its mechanism of action placed it at a regulatory intersection that connects mitochondrial energetics, nuclear gene expression, and whole-body insulin sensitivity. This article covers the molecular biology, the metabolic evidence, and the open questions that define MOTS-c’s current position in the peptide research landscape.

I · Discovery of a mitochondrial-derived signaling peptide

The intellectual history behind MOTS-c begins with a problem that mitochondrial geneticists had been stepping around for years. The mitochondrial genome contains ribosomal RNA genes (12S and 16S) that are structurally homologous to bacterial rRNA, reflecting the endosymbiotic origin of mitochondria from an ancient alphaproteobacterial ancestor. Bacterial rRNA genes occasionally harbor short open reading frames that produce functional peptides, a phenomenon documented in several prokaryotic species, yet the human mitochondrial rRNA regions were assumed to be transcriptionally silent beyond their structural RNA function. Lee and Cohen decided to test that assumption systematically by scanning the 12S rRNA sequence for open reading frames, synthesizing the predicted peptides, and screening them for biological activity in cellular assays.

The screen produced MOTS-c, a 16-amino-acid peptide whose sequence is conserved across vertebrates and whose expression is regulated by metabolic stress signals, particularly AMPK activation and NAD+ depletion.¹ The peptide’s most striking initial property was its subcellular localization: after translation in the mitochondrial matrix, MOTS-c translocated to the nucleus and accumulated there, which suggested a direct signaling role from the mitochondrial genome to the nuclear transcriptional machinery. Cohen’s group demonstrated that MOTS-c binds to nuclear DNA and regulates the expression of genes involved in glucose metabolism, fatty acid oxidation, and the unfolded protein response, effectively acting as a mitochondrial-to-nuclear communication signal that adjusts metabolic gene expression in response to the cell’s energy state.¹

II · Mechanism: AMPK activation and insulin sensitization

AMPK sits at the center of metabolic regulation in a position that Dr. Alex describes as the cellular fuel gauge that integrates inputs from nutrient availability, exercise, hypoxia, and hormonal signals before committing the cell to either energy storage or energy expenditure. When AMPK is phosphorylated at Thr172 (its activation loop residue), the kinase cascade that follows redirects glucose transporters (GLUT4) to the cell surface, phosphorylates acetyl-CoA carboxylase to disinhibit fatty acid oxidation, and suppresses mTORC1 activity to reduce protein synthesis and cell growth. MOTS-c activates this cascade through a mechanism that is pharmacologically distinct from the classical AMPK activators (metformin, AICAR, exercise), because it requires the folate cycle intermediate 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) as a cofactor for its AMPK-stimulating activity.²

Lee and Cohen’s 2018 follow-up study in Cell Metabolism demonstrated that MOTS-c physically interacts with the folate cycle enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase), which catalyzes the final two steps of de novo purine biosynthesis and generates the AICAR that accumulates when the cycle is disrupted. The finding tied MOTS-c to one-carbon metabolism, a pathway that is critical for nucleotide synthesis, methylation reactions, and redox balance, and suggested that the peptide’s metabolic effects might extend beyond AMPK activation to include broader regulation of the methyl donor pool that influences epigenetic marks across the genome.²

The insulin-sensitizing downstream consequence is what makes MOTS-c relevant to metabolic disease research. In high-fat-diet mouse models, MOTS-c administration reduced hepatic glucose production, increased skeletal muscle glucose disposal, and improved insulin tolerance test results to a degree comparable to exercise training, and the effect was AMPK-dependent because AMPK knockout mice showed no metabolic response to MOTS-c.¹ Dr. Shayan Sen notes that the magnitude of glucose improvement in the rodent studies (approximately 20% to 30% reduction in fasting glucose and insulin levels at doses extrapolated from endogenous MOTS-c concentration ranges) is consistent with what would be expected from a moderate AMPK activator, which places MOTS-c in a pharmacological category that is therapeutically interesting but not likely to produce dramatic effects in isolation.

III · Exercise mimetic properties

The exercise-mimetic classification deserves careful framing because no peptide replicates the full physiological complexity of exercise, which involves mechanical loading, calcium flux, reactive oxygen species signaling, hormonal changes, and dozens of myokine species released from contracting muscle. MOTS-c reproduces a specific slice of the exercise response (the AMPK-dependent metabolic shift toward fatty acid oxidation and away from hepatic glucose output) and does so through a mechanism that is molecularly distinct from the myokine signals (IL-6, irisin, myostatin, BDNF) that dominate the post-exercise signaling environment.

Cohen’s group published data in 2019 showing that MOTS-c treatment in aged mice (equivalent to approximately 65 human years) improved physical performance metrics (rotarod endurance, treadmill running time) by 10% to 15% relative to age-matched controls, and that the improvement correlated with increased mitochondrial DNA copy number and Complex I activity in skeletal muscle.³ The finding is mechanistically coherent: AMPK activation stimulates PGC-1α, the master transcriptional coactivator of mitochondrial biogenesis, and increased mitochondrial density in skeletal muscle is the canonical adaptation to endurance training. The difference is that exercise achieves this through repeated mechanical and metabolic stress over weeks, while MOTS-c achieves it through direct pharmacological AMPK engagement, which raises the question of whether the mitochondrial adaptations are qualitatively identical or simply converge on the same quantitative endpoint through different pathways.

IV · Metabolic effects: glucose handling and fatty acid oxidation

The metabolic data on MOTS-c comes primarily from rodent models, and the effect sizes are consistent across the published literature. Lee and Cohen’s initial 2015 characterization in Cell Metabolism reported that MOTS-c administration to high-fat-diet mice for 7 days reduced fasting blood glucose by approximately 25% and fasting insulin by approximately 30%, with corresponding improvements in glucose tolerance test area under the curve that approached the performance of the chow-fed control group.¹ The mechanism was dissected through tissue-specific knockout experiments: AMPKα2 (the skeletal muscle isoform) knockout mice showed no glucose disposal response to MOTS-c, confirming that the peripheral insulin sensitization effect runs through muscle AMPK, while the hepatic glucose suppression effect was partially AMPK-independent and involved MOTS-c-mediated inhibition of the transcription factor FOXO1, which controls gluconeogenic gene expression (PEPCK, G6Pase).

The fatty acid oxidation piece was characterized through indirect calorimetry experiments that measured respiratory exchange ratio (RER), a metric that indicates the relative contribution of carbohydrate versus fat to whole-body energy expenditure. MOTS-c-treated mice showed a 5% to 8% reduction in RER (indicating greater fat oxidation) during the dark (active) phase, and this shift was associated with decreased intramyocellular lipid content measured by Oil Red O staining of muscle sections.² Dr. Alex notes that the fatty acid oxidation effect is pharmacologically coherent with AMPK activation (phosphorylated ACC is the rate-limiting enzyme whose disinhibition permits fatty acid entry into mitochondria) but that the magnitude of RER shift observed in rodents is modest compared to what endurance training produces, which is consistent with the partial exercise-mimetic characterization.

The human data is confined to observational studies that measured endogenous MOTS-c levels and correlated them with metabolic parameters. A 2021 study from Cohen’s group reported that plasma MOTS-c concentrations were inversely correlated with BMI, fasting insulin, and HOMA-IR (a measure of insulin resistance) in a cohort of 120 human subjects, and that MOTS-c levels were significantly lower in individuals with Type 2 diabetes compared to metabolically healthy controls.⁴ The correlation does not establish causality (low MOTS-c could be a consequence of metabolic dysfunction rather than a contributing cause), but it is directionally consistent with the rodent intervention data and provides a rationale for measuring MOTS-c as a metabolic biomarker in future clinical studies.

V · The aging connection

The aging connection follows logically from the mechanism. Mitochondrial function declines with age through a combination of accumulating mitochondrial DNA mutations, reduced mitochondrial biogenesis (driven partly by declining PGC-1α expression and activity), impaired mitophagy that allows damaged mitochondria to persist, and reduced NAD+ availability that limits sirtuin-dependent mitochondrial quality control. MOTS-c engages two of these nodes: AMPK activation stimulates PGC-1α and mitochondrial biogenesis, while the folate cycle interaction influences methylation capacity and potentially affects the epigenetic landscape that governs the expression of mitochondrial maintenance genes.²

Dr. Alex frames the aging implication cautiously: MOTS-c supplementation in aged organisms may partially restore a signaling axis that is physiologically active in young organisms and progressively lost with age, which is the same logic that supports NAD+ precursor supplementation and metformin’s metabolic effects in aging research. The critical unknown is whether the age-related decline in MOTS-c is a cause or a correlate of mitochondrial dysfunction. If MOTS-c declines because the mitochondrial genome accumulates damage with age and produces less of the peptide, then supplementation may compensate for a primary deficit. If MOTS-c declines as a secondary response to broader metabolic changes (and low MOTS-c is simply a biomarker of mitochondrial health rather than a driver), then supplementation may produce transient pharmacological effects without addressing the underlying biology.

Lee and Cohen’s longevity data is preliminary but directionally interesting. MOTS-c treatment in aged mice extended median lifespan by approximately 8% to 12% in one unpublished dataset referenced in their 2020 review, with the effect concentrated in the later portion of the survival curve (suggesting a compression of morbidity rather than a uniform extension of lifespan).⁴ The Cohen lab has been careful to emphasize that these are mouse data in a single strain under controlled laboratory conditions, and that the extrapolation to human longevity is speculative. The finding that matters for the current research landscape is simpler: MOTS-c produces measurable metabolic improvements in aged organisms that are consistent with its mechanism, and the peptide’s endogenous decline with age creates a plausible rationale for investigating supplementation in metabolic aging contexts.

VI · Current research status and open questions

The research trajectory for MOTS-c will depend on several variables that are mostly outside the control of the academic groups that have characterized its biology. The first variable is intellectual property: Cohen and Lee filed patents covering MOTS-c and its analogs through the University of Southern California’s technology transfer office, and the patent estate’s strength will determine whether a pharmaceutical company or biotechnology startup licenses the molecule for clinical development.¹ The second variable is the competitive landscape: the AMPK activation space is crowded (metformin dominates the diabetes market at generic pricing, and several direct AMPK activators have failed in clinical trials due to cardiac hypertrophy concerns from the AMPKγ2 isoform’s role in cardiac glycogen storage), which means MOTS-c must demonstrate a differentiated safety and efficacy profile to justify clinical investment.

The third variable is delivery. MOTS-c is a 16-amino-acid peptide with a molecular weight of approximately 2.2 kDa, which means it is too large for efficient oral absorption and too small to avoid rapid renal clearance. Subcutaneous injection produces plasma half-lives measured in minutes to hours in rodent models, which is pharmacokinetically unfavorable for a compound whose metabolic effects require sustained AMPK engagement.² Cohen’s group has explored PEGylated MOTS-c analogs with extended half-lives, and a 2023 preprint described a PEG-MOTS-c conjugate that maintained detectable plasma concentrations for approximately 24 hours after a single subcutaneous injection in mice, but the immunogenicity risk of PEGylation and the cost of GMP manufacturing at clinical scale remain unresolved.

The open questions that matter most for anyone tracking MOTS-c as a potential therapeutic are these: Will the rodent metabolic data replicate in human trials when the compound is tested against placebo in a randomized, controlled design? Does the folate cycle interaction create off-target effects on nucleotide metabolism that become apparent only at chronic dosing durations? And does the AMPK activation profile of MOTS-c differ meaningfully from metformin’s AMPK activation (which is indirect, through Complex I inhibition) in ways that produce a differentiated safety or efficacy profile? The Cohen lab has been transparent that these questions can only be answered by a formal clinical development program, and that no amount of mechanistic elegance can substitute for the controlled human data that separates a research peptide from a drug candidate.

¹: Lee, C., Zeng, J., Drew, B.G., et al. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism, 2015. Discovery paper characterizing MOTS-c as a 12S rRNA-encoded peptide with AMPK-dependent metabolic effects in high-fat-diet mouse models.

²: Lee, C., Kim, K.H., and Cohen, P. "MOTS-c Regulates the Folate Cycle and De Novo Purine Biosynthesis." Cell Metabolism, 2018. Follow-up study demonstrating MOTS-c interaction with ATIC and the folate cycle, connecting mitochondrial peptide signaling to one-carbon metabolism.

³: Reynolds, J.C., et al. "MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis." Nature Communications, 2019. Exercise-induced MOTS-c secretion data in humans and physical performance improvements in aged mice with MOTS-c treatment.

⁴: Kim, S.J., et al. "The Mitochondrial-Derived Peptide MOTS-c Is a Regulator of Plasma Metabolome and Insulin Sensitivity in Humans." Aging Cell, 2021. Human observational study correlating circulating MOTS-c levels with metabolic parameters including BMI, HOMA-IR, and Type 2 diabetes status.

⁵: López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. "Hallmarks of Aging: An Expanding Universe." Cell, 2023. Landmark review identifying mitochondrial dysfunction as a primary hallmark of aging with downstream effects on energetics, signaling, and cellular maintenance.